Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas

BACKGROUND: Ovarian carcinoma is extremely sensitive to (platinum-based) chemotherapy; however, most patients will relapse with platinum-resistant disease, badly affecting their prognosis. Effective therapies for relapsing resistant tumors are urgently needed. METHODS: We used patient-derived xenogr...

Descripción completa

Detalles Bibliográficos
Autores principales: Affatato, Roberta, Chiappa, Michela, Guffanti, Federica, Ricci, Francesca, Formenti, Laura, Fruscio, Robert, Jaconi, Marta, Ridinger, Maya, Erlander, Mark, Damia, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160919/
https://www.ncbi.nlm.nih.gov/pubmed/35665077
http://dx.doi.org/10.1177/17588359221095064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160919/
https://www.ncbi.nlm.nih.gov/pubmed/35665077
http://dx.doi.org/10.1177/17588359221095064

Ejemplares similares